Colorectal Mucinous Adenocarcinoma
Associated Genetic Biomarkers
NCI Definition: An invasive colorectal adenocarcinoma characterized by the presence of extracellular mucin pools that contain malignant glandular epithelial structures. The extracellular mucin pools occupy more than 50% of the malignant lesion. 
Colorectal mucinous adenocarcinomas most frequently harbor alterations in KRAS, APC, TP53, BRAF, and PIK3CA .
KRAS Mutation, APC Mutation, KRAS Exon 2 Mutation, TP53 Mutation, and KRAS Codon 12 Missense are the most common alterations in colorectal mucinous adenocarcinoma .
There is 1 clinical trial for colorectal mucinous adenocarcinoma, of which 1 is open and 0 are completed or closed. Of the trial that contains colorectal mucinous adenocarcinoma as an inclusion criterion, 1 is phase 2 (1 open).
Microsatellite is the most frequent gene inclusion criterion for colorectal mucinous adenocarcinoma clinical trials .
Ipilimumab and nivolumab are the most common interventions in colorectal mucinous adenocarcinoma clinical trials.
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 6. This dataset does not represent the totality of the genetic landscape; see paper for more information.